Bavencio's EU Nod A Positive For Pfizer's Oncology Business

Pfizer has co-developed an anti-PD L1 cancer drug Bavencio (avelumab) with Merck, which has now been granted approval to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma from European regulators.